Cholesterol Lowering and Residual Risk in Diabetes, Type 1
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 125 participants.
Also called NCT05641753
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose other
- Phase
- Phase 4
- Enrolled
- 125 participants
- Registry
-
NCT05641753
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT05641753. Allocation not applicable; no masking; primary purpose other. Start 2022-12-06 (actual); primary completion 2027-07-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Cholesterol Lowering and Residual Risk in Diabetes, Type 1
- Acronym
- CHORD1
- Condition
- Type 1 Diabetes
- Intervention (Drug)
- Evolocumab Cartridge
- Intervention (Drug)
- Atorvastatin Calcium Tablets
- Intervention (Drug)
- Ezetimibe Tablets
- Intervention (Drug)
- 18F-FDG
- Intervention (Device)
- Angiocatheter 20IV
- Intervention (Device)
- J-Wire
- Intervention (Device)
- GlycoCheck Glycocalyx Measurement Software
- Lead sponsor
- NYU Langone Health
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
Record details
- Record id
cardio:ct-nct05641753- Content hash
9a11ede16340a941c230403659a54caa0e44afa56a4143939245f7a402ebd5e8